A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-25

Study Completion Date

2017-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

NCT04097938

Healthy

COMPLETED PHASE1

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

NCT04976270

Healthy

COMPLETED PHASE1

First-in-Human Single and Multiple Dose of GLPG1972

NCT02612246

Healthy

COMPLETED PHASE1

First-in-Human Single and Multiple Dose of GLPG1690

NCT02179502

Healthy

COMPLETED PHASE1

First-in-Human Single and Multiple Dose of GLPG1837

NCT02325037

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLPG2737 single dose

Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order

Group Type EXPERIMENTAL

GLPG2737 single dose

Intervention Type DRUG

GLPG2737 oral suspension, single ascending doses

Placebo single dose

Single doses of Placebo oral suspension

Group Type PLACEBO_COMPARATOR

Placebo single dose

Intervention Type DRUG

Placebo, oral suspension.

GLP2737 multiple dose

Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order

Group Type EXPERIMENTAL

GLPG2737 multiple dose

Intervention Type DRUG

GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

GLPG2737 multiple dose

Multiple doses of Placebo oral suspension

Group Type PLACEBO_COMPARATOR

GLPG2737 multiple dose

Intervention Type DRUG

Placebo, oral suspension, daily for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLPG2737 single dose

GLPG2737 oral suspension, single ascending doses

Intervention Type DRUG

Placebo single dose

Placebo, oral suspension.

Intervention Type DRUG

GLPG2737 multiple dose

GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

Intervention Type DRUG

GLPG2737 multiple dose

Placebo, oral suspension, daily for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male between 18-50 years of age, inclusive, on the date of signing the Informed Consent Form (ICF).
2. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration.

Clinical safety laboratory test results must be within the laboratory reference ranges for males or test results that are outside the reference ranges for males need to be considered non clinically significant in the opinion of the investigator. One retest is allowed if deemed appropriate by the investigator.
3. Liver function tests must meet the following criteria:

1. aspartate aminotransferase (AST), ALT or alkaline phosphatase (ALP) \<1.2x the upper limit of normal (ULN)
2. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable. One retest is allowed if deemed appropriate by the investigator.
4. Subject's screening ECG is considered normal or abnormal but clinically non-significant. QTcF must not exceed 450 msec. First degree heart block will not be considered as a significant abnormality.
5. Forced expiratory volume in 1 second (FEV1) ≥ 80% of predicted normal for age, gender and height at screening.
6. Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.
7. Negative drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) prior to dosing.
8. Able and willing to comply with the prohibitions and restrictions as described in the protocol and with the contraceptive requirements as described in the protocol.
9. Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations.

Exclusion Criteria

1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A.
3. History of or a current immunosuppressive condition (e.g., human immunodeficiency virus \[HIV\] infection type 1 and 2).
4. Clinically significant illness in the 3 months before screening.
5. Presence or having sequelae of gastrointestinal, liver (except for Gilbert's syndrome), kidney (creatinine clearance ≤ 80 mL/min using the Cockcroft-Gault formula: if calculated result ≤ 80 mL/min, a 24 hour urine collection to determine actual value can be done) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
6. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
7. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5-half-lives of the drug (whichever is longer) before the initial drug administration.
8. Active drug or alcohol abuse (an average intake of more than 21 glasses of wine or beer or equivalent/week) within 2 years prior to screening.
9. Participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug, if the half-life is known (whichever is longer) prior to screening.
10. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes